oxotremorine has been researched along with Parkinson Disease, Secondary in 7 studies
Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "N-carbamoyl-2-(2,6-dichlorophenyl) acetamidine hydrochloride (LON 954) causes a reproducible rest tremor in mice, of rapid onset and short duration with no associated rigidity or akinesia and in the absence of any marked changes in body temperature or accompanying peripheral parasympathomimetic effects." | 3.65 | The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954. ( Coward, DM; Doggett, NS, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kryzhanovskiĭ, GN | 1 |
| Atadzhanov, MA | 1 |
| Voronina, TA | 1 |
| Nerobkova, LN | 2 |
| Silvestrini, B | 1 |
| Lisciani, R | 1 |
| Mendez, JS | 1 |
| Finn, BW | 1 |
| Coward, DM | 1 |
| Doggett, NS | 1 |
| Gugutsidze, DA | 1 |
| Boronina, TA | 1 |
| Horst, WD | 1 |
| Pool, WR | 1 |
| Spiegel, HE | 1 |
| Kolla, VE | 1 |
| Obvintseva, LM | 1 |
7 other studies available for oxotremorine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[The characteristics of a parkinsonian syndrome induced in an experiment by a deficiency of nigrostriatal dopamine and by stimulation of the cholinergic neurons of the caudate nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholine; Animals; C | 1993 |
Experimental data suggesting an adrenergic mechanism in the production of parkinsonian symptoms.
Topics: 5-Hydroxytryptophan; Animals; Atropine; Clonidine; Female; Fenclonine; Imipramine; Male; Mice; Mice, | 1976 |
Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats.
Topics: Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Dopamine; Dose-Response Relationship, Drug; | 1975 |
The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Drug Evaluation, Preclinical; | 1977 |
[Analysis of sleep-wakefulness structure in parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and oxotremorine].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electroencephalography; Hippocampus; Oxotremo | 1989 |
Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Blepharoptosis; Brain; | 1973 |
[Tremorine as test for evaluating antitremor agents (a review of the literature)].
Topics: Animals; Cats; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Guinea P | 1973 |